IP Library Granted Patent US 8,404,252
Granted Patent B2
US 8,404,252 · App. 12/668,258 · Granted Mar 26, 2013

Patent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,404,252
App. No.
12/668,258
Granted
Mar 26, 2013
Kind
B2
Abstract

The present invention provides antigens and vaccines useful in prevention of infection by Yersinia pestis . The present invention provides pharmaceutical compositions of such antigens and/or vaccines. The present invention provides methods for the production of Y. pestis protein antigens in plants, as well as methods for their use in the treatment and/or prevention of Y. pestis infection.

Claims (19)

1. An isolated antigen comprising a Yersinia pestis protein fused to a modified thermostable protein; wherein the Yersinia pestis protein comprises a full-length F1 protein that is at least 95% identical to the sequence set forth as SEQ ID NO: 1, 3, 5, or 7, and wherein the modified thermostable protein is a LicKM protein.

2. The isolated antigen of claim 1 , wherein the Yersinia pestis protein comprises an amino acid sequence that is at least 98% identical to the sequence set forth as SEQ ID NO: 1, 3, 5, or 7.

3. The isolated antigen of claim 1 , wherein the Yersinia pestis protein comprises the amino acid sequence set forth as SEQ ID NO.: 1, 3, 5, or 7.

4. The isolated antigen of claim 1 , wherein the Yersinia pestis protein fused to the modified thermostable protein is one or more of an N-terminal fusion, a C-terminal fusion, or a surface loop insertion fusion protein.

5. A vaccine composition comprising a pharmaceutically acceptable carrier and an antigen comprising a Yersinia pestis protein fused to a modified thermostable protein, wherein the Yersinia pestis protein comprises a full-length F1 protein that is at least 95% identical to the sequence set forth as SEQ ID NO: 1, 3, 5, or 7;

wherein the modified thermostable protein is a LicKM protein; and wherein the composition is capable of eliciting an immune response upon administration to a subject.

6. The vaccine composition of claim 5 , wherein the Yersinia pestis protein comprises an amino acid sequence that is at least 98% identical to the sequence set forth as SEQ ID NO: 1, 3, 5, or 7.

7. The vaccine composition of claim 5 , wherein the Yersinia pestis protein comprises the amino acid sequence set forth as SEQ ID NO.: 1, 3, 5, or 7.

8. The vaccine composition of claim 5 , wherein the Yersinia pestis protein fused to the modified thermostable protein is one or more of an N-terminal fusion, a C-terminal fusion, or a surface loop insertion fusion protein.

9. The vaccine composition of claim 5 , wherein the antigen is produced in a plant selected from a transgenic plant and a plant transiently expressing the antigen.

10. The vaccine composition of claim 5 , wherein the composition comprises antigen which is purified, partially purified, or unpurified from plant cells, a plant, seeds, fruit, or an extract thereof.

11. The vaccine composition of claim 5 , further comprising at least one vaccine adjuvant.

12. The vaccine composition of claim 11 , wherein the adjuvant is selected from the group consisting of complete Freund's adjuvant, incomplete Freund's adjuvant, alum, MF59, saponin, aluminum hydroxide, QuilA, and macrophage-activating lipopeptide (Malp-2).

13. A method for inducing a protective immune response against Yersinia pestis infection in a subject comprising administering to a subject an effective amount of an anti- Yersinia pestis vaccine composition, wherein the administration is sufficient to stimulate production of antigen specific antibodies or stimulate a cellular immune response by the subject; thereby inducing a protective immune response; wherein the vaccine composition comprises an antigen comprising a Yersinia pestis protein fused to a modified thermostable protein; and wherein the Yersinia pestis protein comprises a full-length F1 protein that is at least 95% identical to the sequence set forth as SEQ ID NO:1, 3, 5, or 7; and wherein the modified thermostable protein is a LicKM protein.

14. The method of claim 13 , wherein the composition is administered orally, intranasally, subcutaneously, intravenously, intraperitoneally, or intramuscularly.

15. The method of claim 14 , wherein the composition is administered orally via feeding plant cells to the subject.

16. The method of claim 13 , wherein the subject is human.

17. The method of claim 13 , wherein the Yersinia pestis protein comprises an amino acid sequence that is at least 98% identical to the sequence set forth as SEQ ID NO: 1, 3, 5, or 7.

18. The method of claim 13 , wherein the Yersinia pestis protein comprises the amino acid sequence set forth as SEQ ID NO: 1, 3, 5, or 7.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2014
From: FRAUNHOFER USA, INC.
To: IBIO, INC.
Reel/Frame 033906/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2010
From: YUSIBOV, VIDADI; METT, VADIM; MUSIYCHUK, KONSTANTIN
To: FRAUNHOFER USA, INC.
Reel/Frame 024357/0270 →